A U.S. House Appropriations Committee directed the FDA to reform how it signs off on investigational new drug (IND) applications for new clinical trials. The committee cited concerns that regulatory timing could cause the U.S. to fall behind China and other regions in getting studies started, adding political pressure for faster trial initiation and process changes that affect biotech development timelines.